The Inflation Reduction Act of 2022 (IRA) made the most significant structural changes to Medicare Part D since the program launched in 2006. The changes rolled out in phases: a $35/month insulin cap in 2023, free vaccines in 2023, a $2,000 OOP cap in 2025 (which eliminated the donut hole), and the first-ever Medicare drug price negotiations with results effective January 1, 2026. In 2026, the cap adjusts to $2,100 under the IRA's built-in inflation-indexing formula.
Before 2025, Part D had a three-phase structure: deductible, initial coverage, and then a coverage gap (the donut hole) where beneficiaries paid a much larger share before reaching catastrophic coverage. The IRA collapsed this into two stages starting in 2025: a deductible period (up to $615 in 2026) and an initial coverage period where you pay roughly 25% coinsurance until you hit the $2,100 OOP cap. After $2,100, the plan covers 100% of drug costs for the rest of the calendar year. Costs that count toward the cap include your deductible, copays, and coinsurance, but not your plan premium.
Separately, the IRA's drug price negotiation provision took effect for the first time in 2026. CMS negotiated Maximum Fair Prices (MFPs) for ten high-spend Part D drugs, with negotiated prices ranging from 38% to 79% below their pre-negotiation list prices. A second round of 15 drugs has been selected with negotiated prices effective January 1, 2027, including Ozempic, Wegovy, and Rybelsus (semaglutide). To check your Medicare eligibility or see if your income qualifies for Extra Help (the Part D Low Income Subsidy), use the tools linked at the bottom of this page.
What Medicare Part D 2026 Cap Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same medicare part d 2026 cap can cost many times more at a hospital than at your local pharmacy:
2026 Medicare Part D 2026 Cap Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Annual plan deductible (2026 maximum) | Up to $615/year | You pay 100% of drug costs until the deductible is met; some plans have lower or $0 deductibles |
| Initial coverage coinsurance | 25% of drug cost | After the deductible, you pay roughly 25% until your OOP spending hits $2,100 |
| Annual OOP cap (catastrophic coverage) | $2,100/year then $0 | After $2,100 in OOP spending on covered drugs, the plan pays 100% for the rest of the calendar year |
| Insulin (Part D monthly cap) | $35/month maximum | IRA insulin cap effective January 2023; applies to all covered insulin regardless of plan or deductible |
| Extra Help / Low Income Subsidy (LIS) | $0 to $12.65/drug | For beneficiaries at or below 150% FPL; full subsidy covers deductible and nearly all cost-sharing |
2026 parameters published by CMS in final Part D redesign instructions. Amounts that count toward the $2,100 OOP cap: deductible, copays, and coinsurance. Plan premiums and costs for non-covered drugs do NOT count toward the cap.
Source: CMS Final CY 2026 Part D Redesign Program Instructions; CMS Medicare Part D Benefit Parameters 2026
Why Hospitals Charge So Much
The IRA's $2,100 cap eliminates the catastrophic cost exposure that previously existed for Medicare beneficiaries with complex drug regimens. Before 2025, a beneficiary taking specialty drugs like Enbrel ($7,106 list price per month) or Stelara ($13,836 per month) could face uncapped exposure in the donut hole, which required paying 25% of the list price with no annual ceiling. The 2025 donut hole elimination and the 2025-2026 OOP cap structure together changed that math fundamentally.
Drug manufacturers absorb a portion of the cost above the OOP cap under the IRA's manufacturer discount program. In the catastrophic phase, plans pay 60%, manufacturers pay 20%, and Medicare pays 20%. This structure gives manufacturers an incentive to negotiate their prices, since the IRA's negotiation program also sets Maximum Fair Prices. Plans that previously enjoyed high rebates on branded drugs now share more cost risk under the redesigned benefit, which is part of why 2026 plan premiums vary significantly across Part D options.
The Medicare Prescription Payment Plan (also called the smoothing option) is separate from the OOP cap mechanics. It does not reduce your total cost; it spreads your OOP spending across the calendar year as monthly installments billed by your plan rather than paid at the pharmacy counter. Beneficiaries with high costs early in the year (for example, a specialty drug filled in January) benefit most from the smoothing option. There is no interest, no fees, and a grace period of at least two months if you miss a payment. As of 2026, plans must automatically re-enroll participants who opted in during 2025.
Patient Assistance Programs
Beneficiaries with low income can qualify for Extra Help (the Part D Low Income Subsidy), which dramatically reduces their Part D cost-sharing. In 2026, Extra Help is available to individuals with income up to 150% of the Federal Poverty Level ($23,475 per year for a single person) and limited assets.
Patient assistance programs for Medicare Part D 2026 Cap| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Medicare Extra Help (Low Income Subsidy) | $0 deductible; $1.60 to $12.65 per drug; $0 after OOP cap | ssa.gov/extrahelp |
| State Pharmaceutical Assistance Programs (SPAPs) | Varies by state; may supplement Part D coverage for costs between plans | medicare.gov/plan-compare |
| NeedyMeds Drug Assistance Programs | Free or reduced-cost medications through manufacturer PAPs for income-qualified applicants | needymeds.org |
Extra Help income limits use 2026 Federal Poverty Guidelines. Asset limits: $17,220 (individual), $34,360 (couple). Apply through Social Security at ssa.gov or by calling 1-800-772-1213.
Source: SSA Extra Help program, Medicare.gov, NeedyMeds.org
Medicare Part D
Medicare Part D is the outpatient prescription drug benefit available to anyone enrolled in Medicare (Part A and/or Part B). You get Part D coverage either through a standalone Prescription Drug Plan (PDP) or as part of a Medicare Advantage plan with drug coverage (MAPD). In 2026, the benefit has two coverage stages: a deductible period (up to $615 maximum) and then an initial coverage period where you pay roughly 25% coinsurance until your cumulative out-of-pocket spending reaches $2,100. After $2,100, the plan covers 100% of covered drug costs for the rest of the calendar year.
Six categories of drugs are considered protected classes under Medicare Part D. Plans must cover substantially all drugs in these categories regardless of tier or prior authorization: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals (anti-HIV), and antineoplastics (anti-cancer). Coverage of drugs in protected classes cannot be subject to step therapy requirements. These protections exist because disrupting a stable regimen in any of these categories can cause serious harm.
The IRA's insulin cap of $35 per month remains in place in 2026 for all Medicare Part D enrollees. This applies to any covered insulin product on your plan's formulary, regardless of the specific brand, whether the deductible has been met, or what tier the insulin is placed on. If a pharmacy charges more than $35 per month for insulin to a Part D enrollee, that is a billing error. The $35 cap was established by the IRA signed August 16, 2022 and took effect January 1, 2023.
Common Medicare Part D 2026 Cap Billing Errors
Part D beneficiaries can encounter several billing errors related to cost-sharing, the OOP cap, and the prescription payment plan. If your cost-sharing does not match your plan's Evidence of Coverage (EOC) document, dispute the charge with your plan:
- Charged more than $35 per month for insulin despite having Part D coverage (effective January 2023)
- Deductible applied to insulin or vaccines that are exempt from the Part D deductible under the IRA
- Continued cost-sharing after reaching the $2,100 annual OOP cap for covered drugs
- Extra Help (LIS) copays not applied when the beneficiary qualifies for Low Income Subsidy
- Non-covered drug cost counted toward the $2,100 OOP cap when it should not count
- Prescription Payment Plan participant still charged at the pharmacy counter instead of receiving the monthly installment bill
Frequently Asked Questions
What is the 2026 Medicare Part D out-of-pocket cap?
The 2026 Medicare Part D out-of-pocket cap is $2,100 per calendar year. This is up from $2,000 in 2025. Under the IRA's inflation-indexing rule, the cap adjusts annually based on average Part D drug expenditure growth. Once you spend $2,100 out of pocket on covered drugs (counting deductibles, copays, and coinsurance but not plan premiums), your plan covers 100% of drug costs for the rest of the year.
Is the Medicare Part D donut hole still a thing in 2026?
No. The coverage gap (donut hole) was permanently eliminated effective January 1, 2025, under the Inflation Reduction Act of 2022. In 2026, Part D has two stages: a deductible period (up to $615 maximum) and an initial coverage period where you pay roughly 25% coinsurance. There is no longer a gap where you pay a higher share before reaching catastrophic coverage.
Which drugs have negotiated Maximum Fair Prices starting in 2026?
Ten drugs have federally negotiated Maximum Fair Prices (MFPs) effective January 1, 2026: Eliquis ($231, down from $521 list), Jardiance ($197, down from $573), Xarelto ($197, down from $517), Januvia ($113, down from $527), Farxiga ($178, down from $556), Entresto ($295, down from $628), Enbrel ($2,355, down from $7,106), Imbruvica ($9,319, down from $14,934), Stelara ($4,695, down from $13,836), and NovoLog/Fiasp ($119, down from $495). These prices are for a 30-day supply and represent discounts of 38 to 79% off list price.
How does the Medicare Prescription Payment Plan (smoothing) work?
The Medicare Prescription Payment Plan lets Part D enrollees spread out-of-pocket drug costs evenly across the calendar year as monthly installments billed by their plan, instead of paying large amounts at the pharmacy. Your plan calculates: remaining OOP balance divided by months left in the year. There is no interest, no fees, and no credit check. If you miss a payment, you get at least a 2-month grace period. Opt in through your plan's member portal. As of 2026, plans must auto-renew 2025 participants.
What is Medicare Extra Help and who qualifies in 2026?
Extra Help (also called the Low Income Subsidy or LIS) is a federal program that reduces Part D cost-sharing for beneficiaries with low income and limited assets. In 2026, you may qualify if your income is at or below 150% of the Federal Poverty Level (roughly $23,475 per year for a single person) and you have assets below $17,220. With full Extra Help, your Part D deductible is $0, you pay $1.60 to $4.90 per generic or $4.90 to $12.65 per brand-name drug, and you pay $0 after the OOP cap. Apply through Social Security at ssa.gov or call 1-800-772-1213.
Does the $2,100 Part D OOP cap include my plan premium?
No. Your monthly Part D plan premium does NOT count toward the $2,100 out-of-pocket cap. The amounts that count are: your plan deductible, copayments, and coinsurance on covered drugs. Costs for non-covered drugs, over-the-counter medications, and amounts paid by Extra Help also do not count. Only your own out-of-pocket spending on covered prescription drugs counts toward the cap.
What drugs are in Round 2 of Medicare price negotiations, effective 2027?
CMS selected 15 drugs for Round 2 negotiations, with negotiated Maximum Fair Prices effective January 1, 2027. The list includes Ozempic, Wegovy, and Rybelsus (all semaglutide formulations by Novo Nordisk), Trelegy Ellipta (GlaxoSmithKline), and Xtandi (Pfizer/Astellas). Announced negotiated prices include $274 for Ozempic/Wegovy/Rybelsus, $175 for Trelegy, and $7,004 for Xtandi for a 30-day supply. These prices take effect January 1, 2027.
Are the 6 protected drug classes affected by the Part D redesign?
Protected class protections remain fully intact in 2026. Medicare Part D plans must cover substantially all drugs in six protected classes: immunosuppressants, antidepressants, antipsychotics, anticonvulsants, antiretrovirals (anti-HIV), and antineoplastics (anti-cancer). Step therapy and prior authorization restrictions are prohibited for these classes. The IRA's OOP cap and donut hole elimination apply to covered drugs in protected classes just as they do to other drugs.
